Related Experiment Video

Updated: Mar 14, 2026

In vitro Assessment of Myocardial Protection following Hypothermia-Preconditioning in a Human Cardiac Myocytes Model
08:22

In vitro Assessment of Myocardial Protection following Hypothermia-Preconditioning in a Human Cardiac Myocytes Model

Published on: October 27, 2020

3.5K

Therapeutic hypothermia to protect the heart against acute myocardial infarction

Matthias Kohlhauer1, Alain Berdeaux1, Bijan Ghaleh1

  • 1Inserm, U955, Équipe 3, 94000 Créteil, France; UMR_S955, DHU A-TVB, UPEC, université Paris Est, 94000 Créteil, France; Université Paris Est, École nationale vétérinaire d'Alfort, 94700 Maisons-Alfort, France.

Archives of Cardiovascular Diseases
|October 4, 2016
PubMed

Insights

Therapeutic hypothermia shows cardioprotective effects in animal heart attack models. However, clinical benefits are limited unless cooling is rapid and initiated before reperfusion.

Area of Science:

  • Cardiology
  • Cardiovascular Research
  • Therapeutic Hypothermia

Background:

  • Therapeutic hypothermia (32-34°C) demonstrates cardioprotective effects in animal models of acute myocardial infarction.
  • Benefits include reduced infarct size, prevention of no-reflow, and improved long-term left ventricular function.

Purpose of the Study:

  • To evaluate the timing of therapeutic hypothermia induction in relation to ischemia and reperfusion for acute myocardial infarction.
  • To reconcile the discrepancy between animal model benefits and clinical trial outcomes.

Main Methods:

  • Review of animal studies demonstrating hypothermia effects during ischemia.
  • Analysis of clinical trial data and meta-analyses focusing on hypothermia timing in acute myocardial infarction patients.
  • Subgroup analysis considering infarct size and cooling speed.

Main Results:

  • Hypothermia benefits in animal models are contingent on induction during the ischemic episode.
  • Clinical trials often show limited benefit, likely due to delayed hypothermia induction post-reperfusion.
  • Meta-analyses suggest potential benefits in large infarctions with rapid, pre-reperfusion cooling.

Conclusions:

  • The timing of therapeutic hypothermia is critical for achieving cardioprotection in acute myocardial infarction.
  • Current clinical strategies may be suboptimal due to delayed cooling.
  • Novel approaches focusing on ultra-fast induction and prehospital cooling may enhance therapeutic efficacy.

Keywords:
Acute myocardial infarctionCardioprotectionHypothermiaHypothermieInfarctus du myocardeSTEMITemperatureTempérature

More Related Videos

Short-Duration Hypothermia Induction in Rats using Models for Studies examining Clinical Relevance and Mechanisms05:00

Short-Duration Hypothermia Induction in Rats using Models for Studies examining Clinical Relevance and Mechanisms

Published on: March 3, 2021

3.3K
Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

1.7K

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
376
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
296
Decreased Body Temperature01:29

Decreased Body Temperature

A decreased body temperature can occur in patients with hypothermia and frostbite. Heat loss with extended cold exposure overpowers the body's ability to create heat, resulting in hypothermia. Core temperature readings help classify hypothermia. Mild hypothermia is temperatures between 32 °C (89.6 °F) and 35°C (95 °F) and is caused by impaired thermoregulation. Moderate hypothermia is temperatures between 28 C (82.4 °F) and 32 °C (89.6 °F) caused by...
1.1K
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
1.2K